"En Bloc" Resection of NMIBC: a Prospective， Single Centre，Randomized Study

Non-muscle Invasive Bladder Cancer Clinical Trial

Official title:

Comparison of the Pathological Stage and Clinical Outcome of en Bloc Transurethral Resection by HybridKnife or Laser Versus Conventional Transurethral Resection for NMIBC: a Prospective, Single Centre, Randomized Study

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03221062
• Other study ID #: JHu
• Status: Not yet recruiting
• Phase: Phase 4
• First received: July 14, 2017
• Last updated: July 18, 2017
• Start date: August 1, 2017
• Est. completion date: July 31, 2021

Study information

• Verified date: July 2017
• Source: Tongji Hospital
• Contact: Jia Hu, MD PhD
• Phone: +86 13986089626
• Email: jiahutjm[@]163.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The traditional method of choice for intravesical resection of bladder tumors is conventional transurethral resection of bladder tumor (cTURBT). However, there has long been an ambition to overcome its biggest limitation, tumor fragmentation. Possible consequences include cell seeding and poor specimen quality, including missing detrusor muscle, thermal tissue damage, and tissue fragmentation. En bloc resection of bladder tumor (ERBT) represents an alternative technique for resection of bladder tumors. There is no doubt that ERBT has huge potential. ERBT provides specimens of high quality that are easy for pathologists to read. In theory, this may sustainably change the view on secondary resection, lead to faster decisions on subsequent treatments, and influence patient prognosis. Thus, there is an urgent need to compare ERBT with cTURBT in a thoroughly planned trial.

Description:

Urothelial bladder cancer (UBC) represents a major worldwide healthcare challenge in western countries as well as in developing countries, both oncologically and economically. Initially, most patients present with nonmuscle invasive bladder cancer (NMIBC) with disease confined to the mucosa (stage Ta, carcinoma in situ) or submucosa (T1) characterized by a far lower mortality rate compared with muscle invasive bladder cancer (MIBC).The vast majority of newly diagnosed are non-muscle bladder cancers (NMIBC) which represents about 75% and can be treated with transurethral resection of bladder tumors (TURBT). Therefore, correct initial staging is critical. The quality of TURBT strongly determines patient prognosis and overall treatment.

Conventional transurethral resection of bladder tumors (cTURBT) causes fragmentation. Possible consequences include cell seeding and poor specimen quality, including missing detrusor muscle, thermal tissue damage, and tissue fragmentation. ERBT is developing concept as an alternative to conventional TURBT. En bloc is identified by using various energy sources or modified resection loops as a promising technique. Such as HybridKnife or laser.

The question has been raised as to whether ERBT is ready for guideline implementation. Only two prospective, randomized trials on ERBT have been published. However, there are details on statistical preparation, patient selection, and definitions of primary and secondry goals are missing. Thus, there is still an urgent need to compare ERBT with cTURBT in a thoroughly planned trial.

This study will be conducted in a single centre at Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Eligible patient presented with papillary bladder tumor will be asked to participate in this study and will be provided with an informed consent form in line with Good Clinical Practise and the Declaration of Helsinki.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 180
• Est. completion date: July 31, 2021
• Est. primary completion date: July 31, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Pathological or histological diagnosis by cystoscopy of primary non-muscle invasive bladder urothelial carcinoma (Ta, T1);

2. Imaging examinations showed the bladder muscle has not been affected, no lymph node metastasis or distant metastasis;

3. Diameter of tumor 1-3cm

4. Number of lesions=3 (The position of small lesions relatively concentrated as one place)

5. Patients who agree to ERBT or cTURBT surgery, and will be effected to the postoperative follow-up treatment such as conventional infusion after the operation

Exclusion Criteria:

1. Tis or non-transitional epithelial tumors

2. Pathological or imaging examinations showed the bladder muscle has not been affected

3. There has surgery contraindications, such as bladder fibrosis

4. Diameter of tumor >3cm or <1cm

5. Number of lesions>3

6. Anteriorly located tumor

7. Received chemotherapy or BCG perfusion therapy in the nearly 3 months

8. Poor performance status is difficult to tolerate surgery

9. The patient refused to sign a consent form

Related Conditions & MeSH terms

• Non-muscle Invasive Bladder Cancer
• Urinary Bladder Neoplasms

Intervention

Device:
• Laser en Bloc Resection
Procedure: Laser en Bloc Resection of bladder tumor Procedure: Hydroknife transurethral resection of bladder tumor Procedure: conventional transurethral resection

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Tongji Hospital

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The pathological staging assessment	The pathological staging assessment for ERBT or cTURBT procedure	one week
Primary	The recurrence rate assessment at resection sites	The recurrence rate assessment at resection sites for ERBT or cTURBT procedure	two year
Secondary	periprocedure complications	Modified Clavien scale will be used for reporting and comparison of periprocedure complications(obturator nerve reflection;bladder perforation)	2 days